SRXH Q2 2025 Earnings EPS Loss of 074 Amidst Stock Decline Atossa Therapeutics Q1 2026 Earnings Narrowed Loss Beats Estimates as Clinical Pipeline Advances YALA Q1 2026 Earnings EPS of 016 Highlights Solid Performance Amid Limited Disclosures PNTG Q1 2026 Earnings EPS Beats Estimates Slightly as Stock Declines Cemtrex Inc CETX Q3 2024 Earnings EPS Misses Estimates as Loss Widens vTv Therapeutics Q1 2026 Earnings EPS Surges to 165 Far Above Estimates Despite No Reported Revenue